Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (Nasdaq: NBIX) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical data, product performance and pipeline progress in movement disorders, neuropsychiatry, endocrinology and metabolic disease. The company regularly issues updates on its flagship VMAT2 inhibitor INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington’s disease, including head-to-head pharmacologic studies, long-term efficacy analyses and peer-reviewed publications.
NBIX news commonly features clinical trial readouts across its pipeline. Recent releases have covered Phase 3 and Phase 4 data for INGREZZA in tardive dyskinesia and Huntington’s disease chorea, a Phase 3 study of valbenazine in dyskinetic cerebral palsy, and Phase 2 results for investigational compounds such as NBI-1070770 in major depressive disorder. Investors and clinicians can also follow updates on late-stage programs including osavampator for major depressive disorder and direclidine for schizophrenia and bipolar mania, as well as next-generation VMAT2 inhibitors and CRF-based therapies for metabolic diseases like obesity.
Another major theme in Neurocrine Biosciences news is financial and corporate reporting. The company announces quarterly net product sales for INGREZZA and CRENESSITY, provides guidance ranges for research and development and selling, general and administrative expenses, and discusses its R&D strategy at events such as its annual R&D Day and healthcare investor conferences. Management presentations at large industry meetings, including the J.P. Morgan Healthcare Conference and other investor conferences, are also highlighted in press releases.
This NBIX news page aggregates these updates so readers can quickly review earnings announcements, clinical milestones, R&D strategy briefings, investor conference appearances and key scientific publications related to Neurocrine Biosciences. For anyone tracking developments in tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, neuropsychiatric disorders or emerging CRF-based metabolic therapies, the news stream provides a concise view of the company’s ongoing activities and disclosures.
Neurocrine Biosciences, Inc. (NBIX) will present at the BofA Securities 2024 Health Care Conference, featuring top executives discussing the company's commitment to developing life-changing treatments for neurological disorders. The conference will be webcasted live and a replay will be available on the company's website. Neurocrine Biosciences has a strong portfolio of FDA-approved treatments and a robust pipeline in late-stage development.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present key information at the European Congress of Endocrinology 2024, including baseline characteristics data from CAHtalyst™ Program of crinecerfont in CAH, and data from modified-release hydrocortisone studies in primary adrenal insufficiency and CAH. The presentations will cover pediatric and adult baseline characteristics data in congenital adrenal hyperplasia, Phase 2 Clinical Study Data for Modified-Release Hydrocortisone, Phase 3 Extension Study Data for Modified-Release Hydrocortisone in CAH, and more.
Neurocrine Biosciences, Inc. (NBIX) supports Tardive Dyskinesia Awareness Week to advocate for routine screening and monitoring of TD, a movement disorder caused by antipsychotic medication affecting approximately 600,000 people in the U.S. annually.
Neurocrine Biosciences presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024, highlighting the need for novel treatments in children and adolescents with Congenital Adrenal Hyperplasia (CAH). The data showcased the challenges in long-term CAH management, emphasizing the limitations of current treatment approaches and the difficulties in disease management as patients age into adulthood. Additionally, positive top-line data from previous Phase 3 clinical studies supported two New Drug Applications submitted to the FDA in April 2024.
Neurocrine Biosciences reported first-quarter 2024 financial results, with INGREZZA net product sales of $506 million, representing 23% growth year-over-year. They also announced FDA approval for INGREZZA SPRINKLE capsules and submitted New Drug Applications for crinecerfont. Positive Phase 2 data for NBI-1065845 in major depressive disorder was highlighted, along with strong financial performance and a robust pipeline, positioning the company as a neuroscience leader.
Neurocrine Biosciences, Inc. announced the U.S. FDA approval of INGREZZA SPRINKLE (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. This new oral granules formulation provides an alternative administration option for patients with swallowing difficulties. INGREZZA SPRINKLE offers three effective dosages and can be easily sprinkled on soft food for oral administration.
Summary not available.
Summary not available.
Summary not available.
Summary not available.